Inpatient Diagnostic Approach for Incidentally Detected Pulmonary Fibrosis

Imaging Confirmation

Obtain a non‑contrast high‑resolution CT (HRCT) of the chest with ≤1.5 mm slices as the first definitive imaging step in hospitalized patients with an incidental finding of pulmonary fibrosis. This rapid HRCT allows precise pattern classification and guides subsequent work‑up. [1][2]
HRCT is 10–20 times more sensitive than plain chest radiography for detecting and characterizing lung parenchymal abnormalities. Therefore, when a chest X‑ray suggests fibrosis, an immediate thin‑section HRCT should be performed. 4
Systematically evaluate HRCT for usual interstitial pneumonia (UIP) patterns (definite, possible, or inconsistent) by looking for subpleural basal predominance, reticular changes, honeycombing, and the absence of features that argue against UIP. Pattern recognition is essential for deciding whether a tissue biopsy is required. [1][2]

Take a detailed occupational and environmental exposure history because identifiable exposures (e.g., organic antigens, mold, birds, silica, asbestos) account for >80 % of ILD cases that have a known cause. Identifying such exposures can re‑classify the disease as hypersensitivity pneumonitis or pneumoconiosis, avoiding unnecessary invasive testing. [1][2]
Screen for extrapulmonary manifestations of connective‑tissue disease (CTD) such as Raynaud’s phenomenon, arthralgias, myalgias, skin changes, sicca symptoms, and muscle weakness. CTD underlies roughly 25 % of ILD cases and may present with lung disease before systemic features appear. [1][2]

Order a baseline laboratory panel that includes a complete blood count with differential, C‑reactive protein, renal and hepatic function tests, antinuclear antibodies (ANA), rheumatoid factor (RF), and anti‑cyclic citrullinated peptide (anti‑CCP) antibodies. This panel helps identify inflammatory, autoimmune, or drug‑induced etiologies that could explain the fibrosis. [1][2]

Perform spirometry with forced vital capacity (FVC) and diffusing capacity for carbon monoxide (DLCO) to establish baseline lung function and disease severity. A ≥5 % decline in FVC over 12 months is associated with an approximately two‑fold increase in mortality, underscoring the prognostic value of these measurements. 7
Measure resting arterial blood gases to evaluate the alveolar‑arterial oxygen gradient and baseline oxygenation status, which assists in risk stratification and informs decisions about invasive procedures. 7

Never label a case as idiopathic pulmonary fibrosis (IPF) without first excluding connective‑tissue disease, even when serologies are only mildly abnormal or systemic features are subtle, because pulmonary involvement can precede overt CTD by years. [1][2]